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Abstract 
Adverse drug reactions (ADRs) in older adults are an important healthcare problem 
since they are frequently a cause of hospitalisation, occur commonly during admission, and 
are an important cause of morbidity and mortality. Older adults are particularly susceptible to 
ADRs because they are usually on multiple drug regimens and because age is associated with 
changes in pharmacokinetics and pharmacodynamics.  
The presentation of an ADR in older adults is often atypical, which further 
complicates its recognition. One potential strategy for improving recognition of ADRs is to 
identify those patients who are at risk of an ADR. The recently developed GerontoNet ADR 
Risk Score is a practical tool for identification of older patients who are at increased risk for 
an ADR and who may represent a target for interventions aimed at reducing ADRs.  
Provision of adequate education in the domain of clinical geriatric pharmacology can 
improve recognition of the ADR. Besides formal surveillance systems, built-in computer 
programmes with electronic prescribing databases and clinical pharmacist involvement in 
patient care within multidisciplinary geriatric teams might help to minimise the occurrence of 
ADRs. In addition, a number of actions can be taken in hospitals to stimulate appropriate 
prescribing and to assure adequate communication between primary and hospital care. In 
older adults with complex medical problems and needs, a global evaluation obtained by 
comprehensive geriatric assessment may be helpful in simplifying drug prescription and 
prioritizing pharmacological and health care needs, resulting in an improvement in quality of 
prescribing. 
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Introduction 
An adverse drug reaction (ADR) may be defined as any noxious, unintended, and 
undesired effect of a drug, excluding therapeutic failures, intentional and accidental poisoning, 
and drug abuse.
[1]
 
ADRs, including drug interactions, in older adults are a very important healthcare 
problem since they are frequently a cause of admission to hospital, occur commonly during 
hospitalisation, and are an important cause of morbidity and mortality.
[2-5]
 Older adults are 
particularly susceptible to ADRs not only due to age-associated changes in pharmacokinetics 
and pharmacodynamics but also because of higher prevalence of co-morbidity, disability, and 
multiple drug regimens.
[6-8]
 
The average rate of ADR–related hospital admissions is 16.6% in older patients 
compared to 4.1% in younger patients with 88% considered preventable.
[9,10]
 Studies 
specifically undertaken in older adults have found that 24 % of patients are admitted due to 
ADR
[2]
 and 14% experience an ADR as an inpatient.
[11, 12]
 Moreover, ADRs in older adults 
can have severe medical and economic consequences. These consequences include an 
increased risk of serious disease, with potential long-term disability, institutionalization, and 
even death, which in turn increase expenditures for medical care.
[13]
 
  
Classification 
ADRs can be classified into two main types: type A or B.
[14]
 Type A refers to ADRs 
that are associated with the pharmacological action of a drug and are dose-related. In addition, 
type A ADRs are common, predictable, and have a low mortality (e.g., digoxin toxicity, 
serotonin syndrome with selective serotonin receptor inhibitors, or anti-cholinergic effects of 
tricyclic antidepressants). In contrast, type B adverse drug reactions are unrelated to the 
pharmacological action of a drug. They are often immunologically mediated (for example 
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penicillin hypersensitivity), are relatively uncommon, and are more serious in nature than type 
A reactions. Type C adverse reactions are associated with long-term therapy and are related to 
cumulative dose (e.g., hypothalamic-pituitary-adrenal axis suppression). While Type D 
adverse reactions occur some time after the use of the drug and are usually dose-related and 
uncommon (e.g., tardive dyskinesia after use of antipsychotics), Type E adverse reactions 
occur soon after withdrawal of the drug (e.g., myocardial ischemia after a beta-blocker 
withdrawal) although they are also uncommon. In contrast, Type F ADRs are often caused by 
a drug-drug interaction, are dose-related, and common.
[15]
 
More than 80% of ADRs leading to hospital admission or accruing during 
hospitalisation are type A. Major drug groups that cause type A adverse drug reactions are 
antibiotics, anticoagulants, digoxin, diuretics, hypoglycaemic drugs, and non-steroidal anti-
inflammatory drugs.
[16, 17]
 
 
Risk factors for ADRs in older adults 
Several factors that alter drug distribution or metabolism can make an ADR more 
likely. These include renal or hepatic function impairment and patient characteristics, such as 
age, number of drugs that the patient is receiving, and co-morbidity.
[18]
 Changes in 
pharmacokinetics and pharmacodynamics also play an important role in the increased risk of 
ADRs in older adults, the most important of which is reduced renal clearance. In addition, 
age-related changes in renal structure may lead to altered drug excretion. Therefore, the 
dosage of a drug eliminated through the kidneys should be adjusted for decreased renal 
function.
[19]
  
The possibility of reduced hepatic metabolism in older age should also be anticipated. 
Consequently, drugs that normally show significant, hepatic, first-pass metabolism may 
instead have a higher bioavailability and faster onset, which will require initiation at lower 
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doses with possible extended administration intervals. Cytochrome P450 oxidation declines 
too, increasing the risk for toxicity and possible drug-drug interactions for drugs that are 
substrates of these enzymes.
[20, 21]
 A rapid decline in serum albumin during acute illness may 
additionally result in altered free-drug kinetics. 
Cardiac output is another system function that can decline substantially with age, the 
chief results of which are lowered blood flow to the kidneys and liver. For high extraction 
drugs this could alter the overall elimination of the drug because the elimination of such 
compounds depends upon blood flow. Moreover, the reduced clearance of such compounds 
will produce an increase in half-life as a result of decreased blood flow. 
[22]
 
In older adults, lean body mass and total body water decrease, with a relative increase 
in total body fat. These changes cause a decreased volume of distribution for hydrophilic 
drugs. The reverse situation occurs with lipid-soluble drugs, which exhibit an increased 
volume of distribution that can lead to altered elimination half-life, although not necessarily 
an altered rate of clearance.
 [23]
 
Pharmacodynamic changes in the end-organ responsiveness to drugs at receptor or 
post-receptor levels result in altered, usually increased, sensitivity to several classes of drugs 
such as anticoagulants, and cardiovascular and psychotropic drugs.
[16]
 Moreover, reduced 
homeostatic mechanisms make older people more prone to adverse effects (e.g., orthostatic 
hypotension is more likely to occur at a ‗normal dose‘ of a vasodilator drug in an old person, 
based on sluggish baroreceptor response).
[24]
 
The role of age as a cause of increased risk of ADRs should be preferably seen in the 
context of accumulated, patient-specific physiological and functional changes, which are 
probably more important than chronological age per se in predicting adverse drug 
reactions.
[25]
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Older adults tend to use multiple drugs as a consequence of several chronic clinical conditions. 
It has been found in the literature that the number of drugs taken among older patients is up to 
6 prescribed medications and up to 3 non-prescribed medications.
[26]
 In particular, frail older 
adults residing in nursing homes are prone to polypharmacy and resultant ADRs. However, 
when addressing polypharmacy we should take into account that several chronic conditions 
frequently require more then one drug in order to be adequately treated (i.e., ‗rational 
polypharmacy‘ resulting from treatment via different mechanisms). Nevertheless, it has been 
shown that polypharmacy positively correlates with an increased risk for ADRs, as well as 
drug-drug and drug-disease interactions.
[27]
 As an illustration, patients taking two drugs face a 
13% risk of adverse drug-drug interactions, which rises to 38% for four drugs, and to 82% if 
seven or more drugs are given simultaneously.
[28]
 On the other hand, polypharmacy can 
increase the risk for medication non-adherence, which consecutively can cause suboptimal 
therapeutic effectiveness and poor clinical response. If not recognized, the non-adherence can 
lead to a dose augmentation of the initial medication or the addition of a second drug, thereby 
increasing the risk for an ADR.
[29]
 In addition, living alone, receiving drugs from different 
prescribers, and having cognitive problems and/or poor knowledge of the drugs prescribed 
have all been suggested to lead to higher risk of non-adherence and consecutive adverse drug 
reactions.
[30]
 
The use of potentially inappropriate medications in older adults has also been 
described as one of the causes of ADRs.
[31]
 Inappropriate prescribing, a potentially 
preventable risk factor for ADRs, occurs frequently and deserves nowadays much more 
attention than in the past due to the explosion in the sheer number of drugs available, less 
overall knowledge in their use by providers, and most importantly, less time for consideration 
in regard to the patient. This is exemplified by a Swedish study of patients 75 years or older in 
which 18% of prescribed medications were found to be inappropriate.
[32]
  
 7 
Several methods and instruments have been developed for the purpose of medication 
appropriateness assessment, and are categorized as implicit (judgment-based) or explicit 
(criteria-based) approaches, or using a combination of both. Using an implicit approach 
means that clinical information of the individual patient is taken into account to judge 
appropriateness. In contrast, explicit criteria tend to be founded on lists of drugs to avoid, or 
indicators for appropriate prescribing for several drugs or diseases.  Explicit criteria used with 
prescription data alone or with clinical data are commonly used to detect inappropriate 
prescribing. 
Since no ideal measure exists, the combination of a structured approach and clinical 
judgment is recommended. Currently, the following tools exist to evaluate potentially 
inappropriate prescribing in older adults: the Beers‘ Criteria,[33] Improved Prescribing in the 
Elderly Tool (IPET),
[34] 
and Screening Tool of Older Persons (STOPP)
[35]
 are explicit 
approaches, while the Medication Appropriateness Index (MAI)
[36]
 is an implicit model.  
 
Recognition and reporting of ADRs – a novel risk score 
Not all clinicians, pharmacists, nurses, or patients are able to recognize ADR. This is 
due to various reasons including education and previous experience. The presentation of an 
ADR in older adults is often atypical and non-specific, which further complicates its 
recognition. The ADR may therefore mistakenly be ascribed to the onset of a new medical 
problem or an already existing diagnosis. In that sense, various clinical symptoms such as 
delirium, drowsiness, light-headedness, apathy, dyspepsia, anorexia, chronic constipation, 
urinary incontinence or retention, and falls are often accepted as a primary diagnosis rather 
than secondary to medication.
[37]
 With respect to falls, the use of sedatives and hypnotics, 
antidepressants, and benzodiazepines has shown significant association in the older 
population.
[38]
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The difficulty in distinguishing drug-induced symptoms from a definitive medical 
diagnosis often results in the addition of yet another drug to treat the symptoms, which 
increases the risk of drug-drug interactions and ADR- a phenomenon known as ‗the 
prescribing cascade‘.[37] Therefore, in an attempt to improve ADR recognition in older adults, 
its diagnosis should routinely be a part of the broader diagnostic approach. In older patients 
taking drugs, the differential diagnosis should always include the possibility of adverse drug 
effects.  However, if the patient is taking several drugs it is not always easy to distinguish 
which drug, if any, is causative. When a drug is suspected as the cause of an acute change in a 
patient‘s clinical condition, the clinician should initially consider the known adverse effects of 
the particular drug. This is limited by the knowledge that not all adverse affects are reported 
or documented, particularly for recently marketed drugs. If the suspected reactions involve a 
known toxicity of a particular drug, then the link between the onset of the reaction and drug 
administration should be established. Other conditions that may predispose patients to such 
reactions should also be considered.  
Several criteria have been proposed as a structured causality assessment of ADRs.
[39] 
One of the often-used criteria in addition to the Naranjo algorithm
[40]
 is the WHO–UMC 
(World Health Organization–Uppsala Monitoring Centre) system of causality categories 
(Table 1).
[41]
 The WHO-UMC has been developed as a practical tool for the assessment of 
case reports in daily clinical practice. 
Another important risk factor for developing an ADR is previous occurrence. Re-
exposure to offending drugs due to poor documentation can cause the patient to experience 
the same ADR again. Therefore, it is important to stress the need for accurate documentation 
of ADR at the time of the event and to provide relevant information to the patient about ADR 
in order to prevent further occurrence.
[42] 
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There is increasing interest among clinicians and researchers to find ways to reduce 
ADR occurrences. Prevention of ADR by identifying individuals at high risk is central to 
improving patient care and outcomes. One potential strategy for prevention is to identify those 
patients who are at risk of an ADR and to target additional resources toward this group. An 
example of this approach might be that when a patient is identified as being at risk, the 
physician and/or the pharmacist pay extra attention to all the medications that he or she 
receives. 
In addition to numerous scales that are used in geriatric medicine to identify risks (e.g., 
cardiovascular), disorders (e.g., depression), and dysfunctions (e.g., cognitive problems and 
disability in activities of daily living or instrumental activities of daily living), there has been 
a need to develop a practical score to detect older patients who are at risk for an ADR.  
Hospitalized older adults are usually ‗frail‘ and present with acute diseases, which may 
increase their susceptibility to ADRs and intensify the severity of drug-related illnesses.
[43]
 
Moreover, in-hospital patients, who often have a genuine need for many drugs, are usually the 
victims of a ‗prescribing cascade‘ that leads to an increased likelihood of ADRs.[37] Also, 
because of these complexities in prescribing, older adults often receive inappropriate drugs 
whose risks outweigh the benefits.
[44]
 Therefore, the hospital is an ideal setting to study ADRs 
because pharmacological non-compliance is reduced and the daily evaluation of patients, as 
well as the constant review of charts and medical records, provides an opportunity for careful 
reporting of all suspected ADRs. This opportunity makes the in-hospital population an ideal 
group to study ADRs and to develop a score to assess the risk of drug-related illness.  
Based on these considerations, a group of researchers from four European universities, 
all belonging to the GerontoNet group, a network of academic departments of geriatric 
medicine in the European Union, recently developed and validated a practical, efficient, and 
simple method of identifying patients who are at increased risk of an ADR in a population of 
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in-hospital older adults.
[45]
 This score was developed based on (a) data from the medical 
literature and (b) secondary analysis of the Gruppo Italiano di Farmacoepidemiologia 
nell‘Anziano (GIFA) (Italian Group of Pharmacoepidemiology in the Elderly) database, a 
study that was specifically designed to collect data about ADRs among in-hospital patients in 
Italy. Thereafter, this score was validated in a population of older adults consecutively 
admitted to 4 university hospitals in Europe. 
The mean age of the 5936 participants in the GIFA study was 78.0 years (SD [standard 
deviation] 7.2), and the mean number of drugs used during the hospital stay was 6.3 (SD 3.6). 
Overall, the occurrence rate of ADRs was 6.5%. The number of drugs and a history of a 
previous ADR were the strongest predictors of ADRs, followed by heart failure, liver disease, 
presence of four or more co-morbidities, and renal failure. The ability of the risk score to 
predict ADRs was 0.71. The variables mentioned were retained in a stepwise regression 
model and used to compute the ADR risk score. 
The mean age of the 483 patients in the validation study was 80.3 years (SD 7.6) and 
the mean number of drugs used during the hospitalisation was 11.0 (SD 7.0). Overall, the 
occurrence rate of ADRs was 11.6%. The variables associated with ADRs and included in the 
risk score were four or more co-morbid conditions (1 point), heart failure (1 point), liver 
disease i.e. liver function tests more than 2 times the Upper Limit of Normal (1 point), 
number of daily drugs (maximum 4 points for ≥ 8 drugs, 1 point for 5-8 drugs, 0 points ≤ 5 
drugs), previous ADR (2 points) and renal failure i.e. estimated GFR < 60 ml/min (1 point). 
The range of the score was 0 to 10 points. A cut point between 3 and 4 seemed to provide a 
good balance between sensitivity (68%) and specificity (65%) and may be used to identify 
patients at high risk for ADR. The ability of the risk score to predict ADRs in the validation 
study was 0.7. 
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The findings of this study are concordant with previous findings, which demonstrated that the 
number of concomitantly used drugs is the most important risk factor for the occurrence of 
ADRs.
[3, 6, 18, 43, 46-50]
 Also, a history of an ADR was confirmed to be a strong risk factor for a 
subsequent ADR, suggesting that a certain group of patients might be more susceptible to the 
negative effects of drugs because of ethnic, genetic, or cultural factors.
[51]
 Finally, the authors 
confirmed the finding that certain co-morbidities, in particular heart failure, hepatic disease, 
and impaired renal function, may change drug kinetics, leading to an increased risk of 
ADRs.
[52, 53]
  This study proposes the GerontoNet ADR Risk Score as a practical and simple 
tool for identification of older patients who are at increased risk for an ADR and who may 
represent a target for interventions aimed at reducing ADRs (Table 2). The ADR Risk Score 
allows stratification of patients according to the likelihood of developing an ADR and is 
hoped to significantly improve prescribing practice and reduce the occurrence of ADR 
amongst older patients. 
However, this tool still has to be validated in different settings and countries as the 
findings cannot be extrapolated to older persons who are living in the community or in 
nursing homes. Also, the prescribing patterns are different in various countries, as is the 
epidemiology of disease burden. Moreover, in this study, the authors did not assess the risk 
for ADRs in regard to individual drug classes and the preventability of ADRs.  
 
Prevention 
ADRs in older adults are mostly preventable as the majority of ADRs are type A and 
dose-related. Provision of adequate education in the domain of clinical geriatric 
pharmacology with regard to the most common ADRs and the most frequently responsible 
agents together with the relationship of medication and symptoms can improve recognition of 
the ADR. Moreover, knowledge of pharmacological principles and changed pharmacokinetics 
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and drug response is indispensable in promotion of appropriate prescribing.
[54]
 Therefore, 
prescribers have to judiciously judge the need for a particular drug in a patient and to use this 
drug at the lowest dose necessary to achieve benefit. In addition, different strategies can be 
proposed, addressing both patients and treatments: minor co-morbid conditions should be left 
out of consideration, whereas frailty, renal insufficiency, and alteration in cognitive function 
should be taken into account. Treatments should be periodically reconsidered and adapted 
depending on renal function,
[55, 56]
 while poor compliance should be examined and self-
administration of over-the-counter drugs discouraged. Most importantly, occurrence of some 
symptoms should be identified as the adverse consequence of drug administration, the first 
treatment of which is drug withdrawal and not the addition of a new medication.
[57]
  
Appropriate prescribing is not only about drug choice, but careful evaluation of doses, 
duration of therapy, monitoring for adverse reactions, and drug-drug interactions. As older 
adults are often treated by several physicians, there is a risk for polypharmacy and therefore 
the occurrence of adverse drug reactions.  
Currently, the main mechanism for identifying drug or population factors associated 
with ADRs is that of national pharmacovigilance systems.
[15]
 Besides formal surveillance 
systems, all health-care professionals have a responsibility to report adverse drug reactions 
that they detect even if causal links are not certain. Built-in computer programmes or software 
with electronic prescribing databases and greater clinical pharmacist involvement in patient 
care within multidisciplinary geriatric teams might help to highlight inappropriate prescribing 
and minimise the occurrence of ADR.
[5, 58]
  
In addition, a number of actions can be taken in hospitals to stimulate appropriate 
prescribing and to assure adequate communication between primary and hospital care: 
education of caregivers; accurate recording of drugs used; more accurate recording of adverse 
effect history; better instructions to patients about changes in drug regimens and about newly 
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started drugs; and information to first-line professionals (general practitioners, care workers, 
community pharmacists) and the patient‘s caregivers where appropriate about changes in drug 
regimens and advice for follow-up. 
The interplay of the above-mentioned strategies may lead not only to a better 
understanding of changes in pharmacokinetics and pharmacodynamics in older age and a 
better communication between patients and physicians but also to an improved quality of drug 
use and prevention of ADRs. 
[59]
 However, evidence concerning beneficial effects on hard 
endpoints is still scarce probably due to methodological limitations of existing studies.
[44]
 
A key point in preventing ADR relates to the fact that medical complexity of older adults 
should always be considered before prescribing a pharmacological treatment in order to 
minimize the risk of drug-related illness. Also, drugs that have proven clear beneficial effects 
in clinical trials to treat a chronic condition and whose use is indicated in clinical guidelines 
(CGL) should be used carefully in complex older adults. This is because they may interact 
with co-existing diseases or geriatric syndromes, may not be taken correctly because of the 
presence of cognitive deficits or disability, or may be useless because the health expectancy of 
the patient is too short to determine a beneficial effect of the drug.
[60, 61]
 In these situations the 
risk of iatrogenic illness is elevated and may exceed the potential benefit observed from a 
given pharmacological treatment. In this context, it seems clear that a global assessment of 
patients‘ characteristics, including factors mentioned above, is necessary to have a full 
assessment of iatrogenic illness and to improve the quality of prescribing. The traditional 
approach to patients, diseases, and needs does not provide information on these problematic 
areas. In the past decades the comprehensive geriatric assessment (CGA) has been proposed 
as a methodology to provide a more global approach and assessment of older adults and their 
problems, allowing a more specific and sensible care plan for each single patient.
[62]
 CGA is a 
simultaneous, multilevel assessment of various domains by a multidisciplinary team to ensure 
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that problems are identified, quantified, and managed appropriately. This includes assessment 
of medical, psychiatric, functional, and social domains followed by development of a 
management plan, including rehabilitation. Usually the multidisciplinary team will include as 
a minimum experienced medical, nursing, and therapy staff. CGA is considered the 
―technology‖ of geriatrics and its application results in a clear and significant improvement in 
the chances of a patient being alive and in their own home at up to a year after a hospital 
admission as a result of the evaluation of various problematic areas.
[63]
 In addition, it allows a 
complete and global assessment and management of health care problems, including 
evaluation of drugs with the goal of recognizing and prevention of potential drug-related 
problems and improvement in the quality of prescribing. Several studies so far have assessed 
the effect of CGA and management on drug prescribing and drug-related illness, showing a 
substantial improvement in quality of prescription.
[64, 65]
   
A large study of 834 frail older adults admitted to Veterans Hospitals in the US, which 
compared the CGA approach with usual care, showed a 35% reduction in the risk of a serious 
adverse drug reaction, and a substantial reduction in unnecessary and inappropriate drug use 
and in the number of conditions with omitted drugs significantly associated with the 
intervention.
[66]
 However, one needs to be careful in interpreting the generalization and the 
clinical relevance of CGA in less expert settings. 
Results of these studies confirm that in complex older adults, a full and global 
evaluation of the problems and needs obtained by CGA may be extremely helpful in 
simplifying drug prescription and prioritizing pharmacological and health care needs, 
resulting in an improvement in quality of prescribing and in a reduction in the risk of drug 
related illness. For this reason, so far, CGA is the only intervention that has demonstrated a 
reduction in risk of ADR in older adults. 
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In conclusion, detection and prevention of ADR in older adults remains an important 
part of good clinical practice and a challenge for even the most experienced clinician. The 
basic rule in the process of detection an ADR is a simple question: ‗Could this patient's 
condition be due to one or more of the drugs he/she has taken?‘ Particular attention towards 
patients who are at high risk could reduce the impact of ADR both in terms of cost and quality 
of care. 
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Table 1. WHO-UMC Causality Categories 
 
*All points should be reasonably complied with 
 
 
 
Causality 
term 
Assessment criteria* 
Certain  Event or laboratory test abnormality, with plausible time relationship 
to drug intake 
 Cannot be explained by disease or other drug 
 Response to withdrawal plausible (pharmacologically, pathologically) 
 Event definitive pharmacologically or phenomenologically (i.e. an 
 objective and specific medical disorder or a recognised 
 pharmacological phenomenon) 
 Rechallenge satisfactory, if necessary 
 
Probable/ 
Likely 
 
 Event or laboratory test abnormality, with reasonable time 
 relationship to drug intake 
 Unlikely to be attributed to disease or other drugs 
 Response to withdrawal clinically reasonable 
 Rechallenge not required 
Possible  Event or laboratory test abnormality, with reasonable time 
relationship to drug intake 
 Could also be explained by disease or other drugs 
 Information on drug withdrawal may be lacking or unclear 
Unlikely  Event or laboratory test abnormality, with a time to drug intake that 
makes a relationship improbable (but not impossible) 
 Disease or other drugs provide plausible explanations 
 
Conditional/ 
Unclassified 
 
 Event or laboratory test abnormality 
 More data for proper assessment needed, or 
 Additional data under examination 
Unassessable/ 
Unclassifiable 
 
 Report suggesting an adverse reaction 
 Cannot be judged because information is insufficient or contradictory 
 Data cannot be supplemented or verified 
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Table 2. The GerontoNet ADR Risk Score 
  Points 
4 or more co-morbid conditions 1 
Congestive heart failure 1 
Liver disease* 1 
No of drugs:   
   < 5 
   5-7 
   ≥ 8 
 
0 
1 
4 
Previous ADR 2 
Renal failure** 1 
 
*defined as liver function tests >2x Upper Limit of Normal 
* *defined as creatinine clearance < 40 ml/min 
 
